Search company, investor...



Seed VC | Alive

About LensFree

LensFree develops an imaging system that reduces the radiation dose by over 90% and enhances image quality at the same time. The company's technology has the potential to change the current medical imaging market by allowing X-rays to be imaged rather than just projected.

Headquarters Location

Zarhin St 13 PO box 2219

Ra'anana, 4366241,



Missing: LensFree's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LensFree's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing LensFree

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LensFree is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,567 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,542 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,901 items

LensFree Patents

LensFree has filed 1 patent.

The 3 most popular patent topics include:

  • Spectroscopy
  • Electromagnetic radiation
  • Geometrical optics
patents chart

Application Date

Grant Date


Related Topics



Medical imaging, Polarization (waves), Acoustics, Spectroscopy, Radiation


Application Date


Grant Date


Related Topics

Medical imaging, Polarization (waves), Acoustics, Spectroscopy, Radiation



Latest LensFree News

SBIR Phase I: Lensfree computational flow cytometer for portable, fast and automated characterization of aquatic microorganisms and other particles

Mar 10, 2022

Award Information Award End Date (Contract End Date):2019-11-30 Small Business Information Abstract The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of a cost-effective high-performance platform to monitor and characterize phytoplankton and other microorganisms in water. Some of these aquatic microorganisms may be toxic or even fatal resulting in significant public health concerns (such as recent "red tide" events in Florida, USA) and drastic economic consequences (i.e. deadly effects of harmful algal blooms on the aquaculture industry). The current state of the art in monitoring technology includes laborious and expensive manual sample collection and evaluation using a benchtop microscope or optical digital imaging system. In contrast, the proposed platform will be transformative by enabling low-cost, portable and fast monitoring and automated characterization of aquatic microorganisms. Therefore, this platform will revolutionize monitoring of aquatic microorganisms and, being low cost, it will enable a much wider application of the technology to other markets. Some of these future applications include more efficient biofuels research and development (via algae monitoring), marine biology science and education, general monitoring of particles and pathogens at the water treatment facilities, production algae monitoring. Therefore, the potential societal impact and commercial potential of the proposed technology is transformative. The proposed project aims to develop and evaluate a portable, rapid, durable and environmentally-stable imaging flow-cytometry technology that will automatically monitor microorganisms, such as phytoplankton and pathogens present in the flowing water, and will be capable of specific classification. Existing optics-based flow-cytometry solutions are expensive and not durable for field use. Unlike lab-based flow cytometers or hand-held assays, the proposed system will not rely on reagents or labeling, and therefore will not need an expert/professional, and will keep the evaluated water unchanged. Thus, it can be installed for continual unattended operation and will be much more cost-effective per test due to elimination of an expert's time, costly reagents and fluorophores. Furthermore, the proposed system will also be integrated with a machine learning engine capable of automated identification of microorganisms as well as other micro-objects of interest. Finally, the proposed system will be evaluated on pre-collected samples of local coastal ocean water to determine the presence of three example types of phytoplankton microorganisms and to provide statistical distribution of all of the detected micro-objects. Therefore, the proposed system will be transformative and provide an innovative and unique capability to expediently survey samples of water and automatically characterize identified micro objects. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. * Information listed above is at the time of submission. *

LensFree Frequently Asked Questions (FAQ)

  • Where is LensFree's headquarters?

    LensFree's headquarters is located at Zarhin St 13, Ra'anana.

  • What is LensFree's latest funding round?

    LensFree's latest funding round is Seed VC.

  • Who are the investors of LensFree?

    Investors of LensFree include Sanara Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.